Nanostructured Drug Sales

Nanostructured Drug Sales Market Outlook

The global nanostructured drug sales market is projected to reach approximately USD 18 billion by the year 2035, growing at a CAGR of around 12% during the forecast period from 2025 to 2035. This rapid expansion is driven by the increasing prevalence of chronic diseases, advancements in nanotechnology, and the growing demand for targeted drug delivery systems. Moreover, the rise in funding for nanomedicine research and development is further bolstering market growth. As pharmaceutical companies recognize the potential of nanostructured drugs in improving therapeutic outcomes and reducing side effects, investments in this sector are also expected to increase significantly. Overall, the market is on a trajectory of innovative growth fueled by both technological advancements and an expanding patient demographic.

Growth Factor of the Market

One of the primary growth factors for the nanostructured drug sales market is the increasing demand for effective and specific drug delivery systems. Nanotechnology allows for the modification of drug properties to enhance bioavailability and solubility, which is particularly important for poorly soluble drugs. Additionally, there is a growing focus on personalized medicine, where nanostructured drugs can be tailored to meet the specific needs of individual patients, optimizing therapeutic efficacy. Furthermore, the rise in chronic diseases like cancer and neurological disorders has escalated the need for innovative treatment options, making nanostructured drugs a pivotal part of the pharmaceutical landscape. Regulatory bodies are also becoming more receptive to the approval of nanomedicines, which is facilitating faster market entry for new products. Lastly, collaborations between pharmaceutical companies and research institutions are expected to drive further advancements in nanotechnology applications within the healthcare sector.

Key Highlights of the Market

• The global market is expected to grow significantly, reaching USD 18 billion by 2035.
• CAGR of approximately 12% during the forecast period from 2025 to 2035.
• Increasing focus on personalized medicine and targeted drug delivery systems.
• Heightened funding and investment in nanotechnology research and development.
• Growing prevalence of chronic diseases such as cancer, driving market demand.

By Product Type

Liposomes:

Liposomes are spherical vesicles that consist of lipid bilayers and are used to encapsulate drugs, enhancing drug delivery and bioavailability. They can carry both hydrophilic and hydrophobic drugs, making them versatile for various therapeutic applications. This capability to encapsulate a diverse range of drugs has led to their increasing adoption in oncology and other fields. The liposomal formulation can help reduce drug toxicity while improving therapeutic efficiency. Additionally, advancements in liposome technology, such as pegylation and targeted delivery strategies, are further expanding their application in nanomedicine. As healthcare professionals seek more effective delivery systems, the demand for liposomes will likely continue to rise, positioning them as a key segment within the nanostructured drug sales market.

Nanocrystals:

Nanocrystals are ultra-fine drug particles that enhance solubility and bioavailability, particularly for poorly soluble drugs. Their unique properties allow them to dissolve more rapidly in biological fluids, which significantly improves the absorption of the active pharmaceutical ingredients. This characteristic is particularly valuable in the treatment of chronic diseases, where timely absorption can greatly affect therapeutic outcomes. Moreover, nanocrystals can be produced using various techniques, including milling and precipitation, thereby allowing for scalable manufacturing processes. The rising need for improved delivery systems in oncology and anti-infective therapies is expected to further propel the demand for nanocrystal formulations over the forecast period.

Polymeric Micelles:

Polymeric micelles are nanoscale aggregates formed by amphiphilic block copolymers, offering a promising approach for drug delivery. They can solubilize hydrophobic drugs in an aqueous environment, providing enhanced stability and prolonged circulation time in the bloodstream. This technology allows for the targeted delivery of chemotherapeutics directly to cancer cells while minimizing systemic toxicity. With ongoing advancements in polymer chemistry, the customization of micelles for specific therapeutic applications is becoming more feasible. Consequently, the adoption of polymeric micelles in treating cancer and other complex diseases is expected to drive significant growth in this product segment within the nanostructured drug sales market.

Solid Lipid Nanoparticles:

Solid lipid nanoparticles (SLNs) are colloidal carriers made from solid lipids that have gained attention for their ability to improve the bioavailability of lipophilic drugs. They offer several advantages, including the ability to provide controlled drug release, enhanced drug stability, and reduced toxicity. SLNs can also be engineered for targeted delivery, making them suitable for a variety of therapeutic applications, including anti-inflammatory and anti-infective treatments. The increasing demand for more effective and safer drug formulations is expected to stimulate the growth of the solid lipid nanoparticles segment in the nanostructured drug sales market.

Dendrimers:

Dendrimers are highly branched, tree-like polymers that serve as potential carriers for drug delivery. Their unique structure allows for a high level of functionalization, enabling the attachment of multiple drug molecules, targeting ligands, or imaging agents. This versatility allows dendrimers to be tailored for specific therapeutic purposes, particularly in oncology and neurology. The ability to improve solubility, stability, and targeted delivery coupled with low toxicity makes dendrimers an attractive option in nanomedicine. As research continues to unveil their potential, the demand for dendrimer-based drug formulations is anticipated to grow within the market.

By Application

Oncology:

The oncology segment is one of the most prominent applications for nanostructured drugs, driven by the need for more effective and less toxic treatment options for cancer patients. Nanoparticles can be engineered to deliver chemotherapeutic agents directly to tumor cells, thereby enhancing drug efficacy while minimizing harmful effects on healthy tissues. This targeted approach not only improves the therapeutic index but also reduces side effects commonly associated with conventional cancer treatments. As high incidences of cancer continue globally, innovation in nanomedicine through the development of novel drug formulations is expected to maintain strong growth in this segment over the next decade.

Neurology:

The neurology segment is gaining momentum as advances in nanotechnology pave the way for new drug delivery systems capable of crossing the blood-brain barrier, a significant challenge in treating neurological disorders. Nanostructured drugs can be engineered to enhance drug solubility, stability, and absorption, leading to improved therapeutic outcomes for conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. As the prevalence of neurological disorders increases, there is a critical demand for innovative treatments, positioning the neurology application as a significant growth driver in the nanostructured drug sales market.

Cardiovascular:

In the cardiovascular application segment, nanostructured drugs are being explored for their potential to deliver therapeutics that can treat various heart-related conditions. Innovations in drug delivery systems, such as nanoparticles tailored for site-specific delivery, are expected to improve outcomes for patients with heart disease by reducing adverse effects and enhancing drug efficacy. As cardiovascular diseases remain one of the leading causes of mortality worldwide, the demand for effective treatments is likely to fuel growth in this segment of the market.

Anti-Inflammatory:

The application of nanostructured drugs in anti-inflammatory treatments is drawing attention due to their ability to modulate immune responses effectively while minimizing side effects. Nanoparticles can improve drug bioavailability and target specific inflammatory sites, enhancing therapeutic outcomes in conditions such as arthritis and chronic inflammatory diseases. As healthcare providers seek more effective solutions for patients suffering from chronic inflammatory conditions, the anti-inflammatory application segment is expected to witness considerable growth in the nanostructured drug sales market.

Anti-Infective:

In the anti-infective application segment, nanostructured drugs are being utilized to combat various infections, particularly those caused by antibiotic-resistant strains. The use of nanoparticles can enhance the delivery of antibiotics, providing higher concentrations at the infection site and overcoming the limitations of traditional formulations. Furthermore, nanoparticles can possess inherent antimicrobial properties, offering a dual mechanism of action. As the threat of antimicrobial resistance continues to rise, the demand for innovative anti-infective strategies is likely to drive significant growth in this segment of the market.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies are a crucial distribution channel for nanostructured drugs, especially for those used in specialized treatments such as oncology and neurology. These pharmacies typically carry a wide range of medications, including advanced formulations that require specific storage and handling conditions. The personalized care provided within hospital settings enhances the likelihood of utilizing nanostructured drugs that require careful management and monitoring. As hospitals increasingly adopt cutting-edge treatment options, the role of hospital pharmacies in the nanostructured drug sales market is expected to grow significantly.

Retail Pharmacies:

Retail pharmacies are essential for the distribution of nanostructured drugs to the general public. They cater to a wide range of patients, including those with chronic conditions who require ongoing medication management. The availability of innovative drug formulations in retail settings increases patient access to advanced treatments. As consumer awareness of nanostructured drug benefits grows, retail pharmacies are likely to expand their offerings of these specialized products, contributing to growth in this distribution channel. Additionally, partnerships between pharmaceutical companies and retail pharmacies may facilitate the launch and distribution of new nanomedicines.

Online Pharmacies:

The rise of online pharmacies has transformed the distribution landscape for nanostructured drugs, providing a convenient access point for patients. With the growing trend of e-commerce in the healthcare sector, online pharmacies are increasingly offering a wide range of medications, including advanced formulations that may not be available locally. This trend is particularly significant for patients with chronic conditions who may require ongoing or specialized treatments not easily accessible through traditional retail pharmacies. As the market for online pharmacy services expands, the distribution of nanostructured drugs through this channel is expected to see substantial growth.

By Ingredient Type

Polyethylene Glycol:

Polyethylene glycol (PEG) is widely used in the formulation of nanostructured drugs due to its biocompatibility and ability to enhance solubility. PEGylation, the process of attaching PEG molecules to drugs, can significantly improve the pharmacokinetics and pharmacodynamics of therapeutic agents. This modification minimizes immunogenicity and prolongs circulation time in the bloodstream, resulting in better therapeutic efficacy. As a popular ingredient in the development of liposomes and polymeric micelles, the incorporation of polyethylene glycol in nanostructured drugs is expected to drive growth in this segment within the market.

Chitosan:

Chitosan, derived from chitin, is gaining traction as an ingredient in nanostructured drug formulations due to its natural origin and favorable properties. Its biocompatibility, biodegradability, and ability to enhance the delivery of poorly soluble drugs make chitosan an attractive option for drug development. Chitosan nanoparticles can also facilitate controlled drug release and are being explored for applications in various therapeutic areas, including anti-inflammatory and anti-infective treatments. As research continues to uncover the benefits of chitosan in nanomedicine, its demand is expected to grow significantly.

Polylactic Acid:

Polylactic acid (PLA) is a biodegradable polymer that is increasingly being utilized in the formulation of nanostructured drugs. Its favorable mechanical properties, along with its ability to encapsulate hydrophobic drugs effectively, make PLA a valuable ingredient for developing nanoparticles and controlled-release drug systems. The use of PLA in drug delivery applications aligns with the growing demand for environmentally friendly solutions, as it is derived from renewable resources. The expanding use of PLA in nanotechnology is anticipated to contribute to growth in this ingredient segment of the market.

Dextran:

Dextran is a polysaccharide that offers unique properties for use in nanostructured drug formulations, particularly in enhancing solubility and stability. Its biocompatibility and ability to form hydrogels make dextran an ideal candidate for drug delivery applications. Dextran-coated nanoparticles can improve the pharmacokinetics of encapsulated drugs, optimizing their therapeutic effects. As interest in using biopolymers for drug formulation increases, dextran is likely to gain traction in the nanostructured drug sales market.

Polyethyleneimine:

Polyethyleneimine (PEI) is a versatile polymer known for its cationic properties, which make it an excellent candidate for gene delivery and other therapeutic applications. Its ability to form complexes with nucleic acids enables targeted delivery to specific cells, particularly in gene therapy. Additionally, PEI's capability to enhance the solubility and stability of drugs has led to its use in various nanostructured drug formulations. As advancements in gene therapies continue, the demand for polyethyleneimine in nanomedicine is expected to rise, further solidifying its position in the market.

By Region

The North American region is anticipated to hold a significant share of the global nanostructured drug sales market, owing to advanced healthcare infrastructure, increased investment in research and development, and a growing number of clinical trials focusing on nanotechnology applications. The United States is at the forefront of this market, contributing substantially to the overall revenue due to its extensive pharmaceutical industry and a rising incidence of chronic diseases, especially cancer and neurological disorders. Additionally, the region's favorable regulatory environment for novel drug formulations enhances the market's growth prospects, with a projected CAGR of approximately 11% during the forecast period.

In Europe, the nanostructured drug sales market is also expected to witness significant growth, driven by the increasing demand for innovative drug delivery systems and a strong focus on personalized medicine. The European market is characterized by an active collaboration between pharmaceutical companies and academic institutions focused on nanomedicine research. Countries like Germany, France, and the United Kingdom are leading in terms of market share due to their advanced healthcare systems and commitment to research and development. Furthermore, the rising awareness regarding the benefits of nanostructured drugs among healthcare professionals and patients is likely to contribute to market expansion in the region.

Opportunities

The nanostructured drug market presents numerous opportunities for growth, particularly in the domain of personalized medicine. As healthcare continues to shift towards individualized treatment plans, the demand for tailored drug delivery systems that can effectively target specific patient populations is on the rise. Nanostructured drugs, with their unique properties of enhancing drug solubility, stability, and bioavailability, are well-positioned to meet these demands. Moreover, ongoing advancements in nanotechnology and material sciences could lead to the development of more sophisticated and effective drug formulations. This creates a fertile ground for pharmaceutical companies to innovate, explore new therapeutic applications, and ultimately enhance patient outcomes across various disease states.

Another promising opportunity lies in the increasing prevalence of chronic diseases globally, which continues to drive demand for innovative treatment options. As conditions such as cancer, diabetes, and cardiovascular diseases become more widespread, there is a pressing need for more effective and targeted therapies. Nanostructured drugs can play a crucial role in addressing these healthcare challenges by improving drug delivery mechanisms and reducing side effects associated with traditional medications. Additionally, regulatory bodies are becoming more supportive of novel drug developments, which could further facilitate market expansion. As such, this growing demand for advanced treatment modalities presents a significant opportunity for stakeholders in the nanostructured drug sales market.

Threats

Despite the optimistic outlook for the nanostructured drug sales market, several threats could impede growth. One of the primary concerns is the regulatory landscape surrounding nanomedicine. Regulatory agencies are still developing frameworks for the approval and oversight of nanostructured drugs, leading to uncertainties in product development and market entry. This lag can create barriers for pharmaceutical companies seeking to bring innovative products to market. Furthermore, the complexity of nanotechnology may result in higher research and development costs, which could deter smaller companies from entering the market. Additionally, the potential for regulatory changes and evolving safety standards could pose challenges that impact the overall growth trajectory of the market.

Another potential threat to the market is the growing public concern regarding the safety and environmental impact of nanotechnology. The perception that nanostructured drugs may pose unknown risks to human health or the environment could result in consumer resistance, regulatory scrutiny, and increased market barriers. Additionally, competition from traditional drug delivery systems may hinder the adoption of nanostructured alternatives. As stakeholders in the pharmaceutical industry work to address these concerns, it will be crucial to provide transparent data on the safety and efficacy of nanostructured drugs to bolster public confidence and drive market growth.

Competitor Outlook

• Amgen Inc.
• Novartis AG
• F. Hoffmann-La Roche AG
• Pfizer Inc.
• Johnson & Johnson
• Sanofi S.A.
• Merck KGaA
• Celgene Corporation
• Siemens Healthineers
• AstraZeneca PLC
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• AbbVie Inc.
• Biogen Inc.

The competitive landscape of the nanostructured drug sales market is characterized by the presence of both established pharmaceutical giants and emerging companies focused on innovative research and development. Larger companies such as Amgen Inc. and Novartis AG have the advantage of substantial financial resources and extensive R&D capabilities, enabling them to invest in advanced nanomedicine technologies and clinical trials. These companies often collaborate with academic institutions and research organizations to stay at the forefront of nanotechnology advancements, ensuring a steady pipeline of novel products. Additionally, the strong brand recognition and established distribution networks of these giants enhance their competitive positioning in the marketplace.

On the other hand, smaller biotech firms and startups are also making significant strides in the nanostructured drug market. Many of these companies focus on niche applications and specialized drug delivery systems that may not be the primary focus of larger corporations. Their agility and innovative approaches allow them to quickly adapt to emerging trends, such as personalized medicine and targeted therapies. This dynamic creates a diverse competitive landscape that fosters innovation and promotes the development of cutting-edge nanomedicines. As a result, collaboration between established companies and startups is becoming increasingly common, further driving advancements in the market.

Some of the major companies in the nanostructured drug sales market include Pfizer Inc. and Johnson & Johnson, both of which have invested heavily in nanotechnology-based products. Pfizer has been involved in research to develop nanoparticle formulations that enhance drug delivery for various therapeutic areas, particularly oncology. Johnson & Johnson has also explored the potential of nanomedicine in delivering targeted therapies. These organizations' commitment to advancing nanotechnology illustrates their recognition of its potential to revolutionize drug delivery methods and improve patient outcomes. The ongoing research and collaboration efforts among these companies will likely shape the future of the nanostructured drug sales market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Merck KGaA
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Biogen Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sanofi S.A.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 AstraZeneca PLC
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Celgene Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Siemens Healthineers
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Gilead Sciences, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 F. Hoffmann-La Roche AG
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Bristol-Myers Squibb Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Nanostructured Drug Sales Market, By Application
    • 6.1.1 Oncology
    • 6.1.2 Neurology
    • 6.1.3 Cardiovascular
    • 6.1.4 Anti-Inflammatory
    • 6.1.5 Anti-Infective
  • 6.2 Nanostructured Drug Sales Market, By Product Type
    • 6.2.1 Liposomes
    • 6.2.2 Nanocrystals
    • 6.2.3 Polymeric Micelles
    • 6.2.4 Solid Lipid Nanoparticles
    • 6.2.5 Dendrimers
  • 6.3 Nanostructured Drug Sales Market, By Ingredient Type
    • 6.3.1 Polyethylene Glycol
    • 6.3.2 Chitosan
    • 6.3.3 Polylactic Acid
    • 6.3.4 Dextran
    • 6.3.5 Polyethyleneimine
  • 6.4 Nanostructured Drug Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Nanostructured Drug Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Nanostructured Drug Sales market is categorized based on

By Product Type

• Liposomes
• Nanocrystals
• Polymeric Micelles
• Solid Lipid Nanoparticles
• Dendrimers

By Application

• Oncology
• Neurology
• Cardiovascular
• Anti-Inflammatory
• Anti-Infective

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Polyethylene Glycol
• Chitosan
• Polylactic Acid
• Dextran
• Polyethyleneimine

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Amgen Inc.
• Novartis AG
• F. Hoffmann-La Roche AG
• Pfizer Inc.
• Johnson & Johnson
• Sanofi S.A.
• Merck KGaA
• Celgene Corporation
• Siemens Healthineers
• AstraZeneca PLC
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• AbbVie Inc.
• Biogen Inc.